Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model

European Journal of Pharmaceutical Sciences

Volumn 39, Issue 5, 2010, Pages 428-436

  Serpe, Loredana ^a   Canaparo, Roberto ^a   Daperno, Marco ^b   Sostegni, Raffaello ^b   Martinasso, Germana ^a   Muntoni, Elisabetta ^a   Ippolito, Laura ^c   Vivenza, Nicoletta ^c   Pera, Angelo ^d   Eandi, Mario ^a   Gasco, Maria Rosa ^c   Zara, Gian Paolo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Gastroenterology Unit   (Italy)

^c NANOVECTOR S R L   (Italy)

^d Fondazione IBD Onlus   (Italy)

Author keywords

Butyrate; Cytokines; Dexamethasone; Inflammatory bowel diseases; Solid lipid nanoparticles

Indexed keywords

BUTYRIC ACID; DEXAMETHASONE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; MESSENGER RNA; SOLID LIPID NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT;

ANTI-INFLAMMATORY AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LIPIDS; MALE; NANOPARTICLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 77549083354     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.01.013     Document Type: Article

References (34)

1. Cavaglieri C.R., Nishiyama A., Fernandes L.C., Curi R., Miles E.A., and Calder P.C. Differential effects of short-chain fatty acids on proliferation and production of pro- and anti-inflammatory cytokines by cultured lymphocytes. Life Sci. 73 (2003) 1683-1690
2. Cavalli R., Gasco M.R., Chetoni P., Burgalassi S., and Saettone M.F. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int. J. Pharm. 238 (2002) 241-245
3. D'Argenio G., Cosenza V., Delle Cave M., Iovino P., Delle Valle N., Lombardi G., and Mazzacca G. Butyrate enemas in experimental colitis and protection against large bowel cancer in a rat model. Gastroenterology 110 (1996) 1727-1734
4. Dianzani C., Cavalli R., Zara G.P., Gallicchio M., Lombardi G., Gasco M.R., Panzanelli P., and Fantozzi R. Cholesteryl butyrate solid lipid nanoparticles inhibit adhesion of human neutrophils to endothelial cells. Br. J. Pharmacol. 148 (2006) 648-656
5. Duncan I.W., Culbreth P.H., and Burtis C.A. Determination of free, total and esterified cholesterol by high-performance liquid chromatography. J. Chromatogr. 162 (1979) 281-292
6. Dyer J.P., Featherstone J.M., and Solomon L.Z. The effect of short-chain fatty acids butyrate, propionate, and acetate on urothelial cell kinetics in vitro: potential therapy in augmentation cystoplasty. Pediatr. Surg. Int. 21 (2005) 521-526
7. Fiocchi C. From immune activation to gut tissue injury: the pieces of the puzzle are coming together. Gastroenterology 117 (1999) 1238-1241
8. Friend D.R. New oral delivery systems for treatment of inflammatory bowel disease. Adv. Drug Deliv. Rev. 57 (2005) 247-265
9. Gasco M.R. Gastrointestinal applications of nanoparticulate drug-delivery systems. In: Thassu D., Deleers M., and Pathak Y. (Eds). Nanoparticulate Drug-Delivery Systems (2007), Informa Health Care, New York 305-316
10. Hanuer S.B. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel Dis. 12 (2006) S3-S9
11. Klampfer L., Huang J., Sasazuki T., Shirasawa S., and Augenlicht L. Inhibition of interferon gamma signaling by the short chain fatty acid butyrate. Mol. Cancer Res. 1 (2003) 855-862
12. Lamprecht A., Ubrich N., Yamamoto H., Schäfer U., Takeuchi H., Maincent P., Kawashima Y., and Lehr C.M. Biodegradable nanoparticles for targeted delivery in treatment of inflammatory bowel disease. J. Pharm. Exp. Ther. 299 (2001) 775-781
13. Lichtenstein G.R., Abreu M.T., Cohen R., and Tremaine W. American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators and infliximab in inflammatory bowel disease. Gastroenterology 130 (2006) 940-987
14. Lucas A., Cobelens P.M., Kavelaars A., Heijnen C.J., Holtmann G., Haag S., Gerken G., Langhorst J., Dobos G.J., Schedlowski M., and Elsenbruch S. Disturbed in vitro adrenergic modulation of cytokine production in inflammatory bowel diseases in remission. J. Neuroimmunol. 182 (2007) 195-203
15. Manjunath K., Reddy J.S., and Venkateswarlu V. Solid lipid nanoparticles as drug delivery systems. Methods Find. Exp. Clin. Pharmacol. l27 (2005) 127-144
16. Manjunath K., and Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Drug Target. 14 (2006) 632-645
17. Menzel T., Lührs H., Zirlik S., Schauber J., Kudlich T., Gerke T., Gostner A., Neumann M., Melcher R., and Scheppach W. Butyrate inhibits leukocyte adhesion to endothelial cells via modulation of VCAM-1. Inflamm. Bowel Dis. 10 (2004) 122-128
18. Nakase H., Okazaki K., Tabata Y., Uose S., Ohana M., Uchida K., Nishi T., Debreceni A., Itoh T., Kawanami C., Iwano M., Ikada Y., and Chiba T. An oral drug delivery system targeting immune-regulating cells ameliorates mucosal injury in trinitrobenzene sulfonic acid-induced colitis. J. Pharm. Exp. Ther. 297 (2001) 1122-1128
19. Nancey S., Bienvenu J., Coffin B., Andre F., Descos L., and Flourié B. Butyrate strongly inhibits in vivo stimulated release of cytokines in blood. Dig. Dis. Sci. 47 (2002) 921-928
20. Pellizzaro C., Coradini D., Morel S., Ugazio E., Gasco M.R., and Daidone M.G. Cholesteryl butyrate in solid lipid nanospheres as an alternative approach for butyric acid delivery. Anticancer Res. 19 (1999) 3921-3926
21. Podolski D.K. Inflammatory bowel disease. N. Engl. J. Med. 347 (2002) 417-449
22. Probert C.S., Chott A., Turner J.R., Saubermann L.J., Stevens A.C., Bodinaku K., Elson C.O., Balk S.P., and Blumberg R.S. Persistent clonal expansion of peripheral blood CD4+ lymphocytes in chronic inflammatory bowel disease. J. Immunol. 157 (1996) 3183-3191
23. Rogler G., Meinel A., Lingauer A., Michl J., Zietz B., Gross V., Lang B., Andus T., Schölmerich J., and Paliztsch K.D. Glucocorticoid receptors are down-regulated in inflamed colonic mucosa but not in peripheral blood mononuclear cells from patients with inflammatory bowel disease. Eur. J. Clin. Invest. 29 (1999) 330-336
24. Säemann M.D., Böhmig G.A., Osterreicher C.H., Burtscher H., Parolini O., Diakos C., Stöckl J., Hörl W.H., and Zlabinger G.J. Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB J. 14 (2000) 2380-2382
25. Salomone B., Ponti R., Gasco M.R., Ugazio E., Quaglino P., Osella-Abate S., and Bernengo M.G. In vitro effects of cholesteryl butyrate solid lipid nanospheres as a butyric acid pro-drug on melanoma cells: evaluation of antiproliferative activity and apoptosis induction. Clin. Exp. Metast. 18 (2001) 663-673
26. Scheppach W., and Weiler F. The butyrate story: old wine in new bottles?. Curr. Opin. Clin. Nutr. Metab. Care 7 (2004) 563-567
27. Segain J.P., Raingeard de la Blétière D., Bourreille A., Leray V., Gervois N., Rosales C., Ferrier L., Bonnet C., Blottière H.M., and Galmiche J.P. Butyrate inhibits inflammatory responses through NFkB inhibition: implications for Crohn's disease. Gut 47 (2000) 397-403
28. Serpe L., Laurora S., Pizzimenti S., Ugazio E., Ponti R., Canaparo R., Briatore F., Barrera G., Gasco M.R., Bernengo M.G., Eandi M., and Zara G.P. Cholesteryl butyrate solid lipid nanoparticles as a butyric acid pro-drug: effects on cell proliferation, cell-cycle distribution and c-myc expression in human leukemic cells. Anticancer Drugs 15 (2004) 525-536
29. Venkatraman A., Ramakrishna B.S., Shaji R.V., Kumar N.S., Pulimood A., and Patra S. Amelioration of dextran sulfate colitis by butyrate: role of the shock protein 70 and NF-kappa B. Am. J. Physiol. Gastrointest. Liver Physiol. 285 (2003) G177-184
30. Vernia P., Anese V., Bresci G., D'Albasio G., D'Incà R., Giaccari S., Ingrosso M., Mansi C., Riegler G., Valpiani D., and Caprilli R. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur. J. Clin. Invest. 33 (2003) 244-248
31. Tagore A., Gonsalkorale W.M., Pravica V., Hajeer A.H., McMahon R., Whorwell P.J., Sinnott P.J., and Hutchinson I.V. Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigens 54 (1999) 386-390
32. Usami M., Kishimoto K., Ohata A., Miyoshi M., Aoyama M., Fueda Y., and Kotani J. Butyrate and trichostatin A attenuate nuclear factor κB activation and tumor necrosis factor α secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutr. Res. 28 (2008) 321-325
33. Zapolska-Downar D., Siennicka A., Kaczmarczyk M., Kołodziej B., and Naruszewicz M. Butyrate inhibits cytokine-induced VCAM-1 and ICAM-1 expression in cultured endothelial cells: the role of NF-kB and PPARα. J. Nutr. Biochem. 15 (2004) 220-228
34. Zara G.P., Cavalli R., Bargoni A., Fundarò A., Vighetto D., and Gasco M.R. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Target. 10 (2002) 327-335